lymphoma dr. p. cross 10 th annual national preparatory course in clinical and radiation oncology
TRANSCRIPT
![Page 1: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/1.jpg)
LYMPHOMALYMPHOMA
Dr. P. CrossDr. P. Cross1010thth Annual National Preparatory Course in Annual National Preparatory Course in
Clinical and Radiation OncologyClinical and Radiation Oncology
![Page 2: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/2.jpg)
WHO Classification of Hematological NeoplasmsWHO Classification of Hematological Neoplasms
Myeloid Lymphoid Histiocytic Mast Cell
B cell neoplasms **
T cell neoplasms
Hodgkin’s lymphoma
** Includes plasma cell myeloma
![Page 3: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/3.jpg)
Proposed WHO Classification of. Lymphoid Neoplasms - 1
B-Cell neoplasmsPrecursor B-cell neoplasm
Precursor B-lymphoblastic leukemia/Iymphoma (precursor B-cell acute lymphoblastic leukemia)
Mature (peripheral) B-cell neoplasm*B-cell chronic lymphocytic leukemia/small lymphocytic lymphomaB-cell prolymphocytic leukemiaLymphoplasmacytic lymphomaSplenic marginal zone B-cell lymphoma (+/— villous lymphocytes)Hairy cell leukemiaPlasma cell myeloma/plasmacytomaExtranodal marginal zone B-cell lymphama of MALT typeNodal marginal zone B-cell lymphoma (+1— monocytoid B cells)Follicular lymphomaMantle-cell lymphomaDiffuse large B-cell lymphamaMediastinal large B-cell lymphomaPrimary effusion lymphoma
Burkitt’s lymphoma/Burlcitt cell leukemia
![Page 4: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/4.jpg)
Proposed WHO Classification of. Lymphoid Neoplasms (cont’d)
T-cell and NK-cell neoplasmsPrecursor T-cell neoplasm
Precursor T-lymnphoblastic lymphoma/leukemia (precursor T-cell acute lymphoblastic leukemia)Mature (peripheral) T-cell neoplasms
T-cell prolymphocytic leukemiaT-cell granular lymphocytic leukemiaAggressive NK-cell leukemiaAdult T-cell lymphoma/leukemia (HTLV1 +)Extranodal NK/T-cell lymphoma, nasal typeEnteropathy-type T-cell lymphomaHepotosplenic gamma-delta T-cell lymphomaSubcutaneous panniculitis-like T-cell lymphomaMycosis fungoides/Sezary syndromeAnaplastic large-cell lymphoma, T/null cell, primary cutaneous typePeripheral T-cell lymphoma, not otherwise characterizedAngioimmunoblastic T-celllymphomaAmaplastic large-cell lymphoma, T/null cell, primary systemic type
Hodgkin’s lymphoma (Hodgkin’s disease)Nodular lymphocyte-predominant Hodgkin’s )ymphomaClassical Hodgkin’s lymphoma
Nodular sclerosis Hodgkin’s Iymphoma (grades 1 and 2)Lymphocyte-rich classical Hodgkin’s lymphomaMixed cellularity Hodgkin’s lymphomaLymphocyte depletion Hodgkin’s lymphoma
NOTE: Only major categories are included. Subtypes and variants will be discussed in the WHO book2 and
are listed in Tables 7 through 16. Common entities are shown in boldface type.Abbreviations: HTLV1 +, human T-cell leukemia virus; MALT, mucosa -associated lymphoid tissue; NK,
natural killer.*B-and T-/NK-cell neoplasms are grouped according to major clinical presentations (predominantly
disseminated/leukemic, primary extranodal, predominantly nodal).
![Page 5: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/5.jpg)
Clinical Grouping of LymphomasClinical Grouping of Lymphomas
1. Indolent
2. Aggressive
3. Highly aggressive
Formerly
1. Low Grade
2. Intermediate Grade
3. High Grade
![Page 6: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/6.jpg)
Clinical Grouping of LymphomasClinical Grouping of Lymphomas
1. Indolent ( “low grade”)
– Follicular lymphoma Grade 1,2 22%– Marginal zone lymphoma
• Nodal 1%• Extranodal (MALT) 5%
– Small lymphocytic lymphoma 6%– Lymphoplasmacytic* 1%
Approximate International Incidence
*association with Waldenstrom’s macroglobulinemia
![Page 7: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/7.jpg)
Clinical Grouping of LymphomasClinical Grouping of Lymphomas
2. Aggressive ( “intermediate grade”)
– Diffuse large B-cell lymphoma 21%
– Primary mediastinal large B cell lymphoma 2%– Anaplastic large T / null cell lymphoma 2%– Peripheral T cell lymphoma 6%– Extranodal NK / T cell lymphoma, nasal type
– Follicular lymphoma Gd 3– Mantle cell lymphoma 6%
Approximate International Incidence
![Page 8: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/8.jpg)
Clinical Grouping of LymphomasClinical Grouping of Lymphomas
3. Highly Aggressive ( ”High grade”)
– Lymphoblastic lymphoma 2%
– Burkitts lymphoma 1%
– Burkitt-like lymphoma 2%
Approximate International Incidence
![Page 9: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/9.jpg)
Clinical Grouping of LymphomasClinical Grouping of Lymphomas(further simplified for radiation oncology exam purposes)
• INDOLENT– Follicular lymphoma Gd 1, 2– MALT (marginal zone lymphoma, extranodal (MALT
type))
• AGGRESSIVE– Diffuse large cell
![Page 10: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/10.jpg)
Lymphoma – Staging SystemLymphoma – Staging System(Cotswold’s Meeting modification of Ann Arbour Classification
I Single lymph node region(or lymphoid structure) **
II 2 or more lymph node regions
III Lymph node regions on both sides of diaphragm
IV Extensive extranodal disease (more extensive then “E”)
![Page 11: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/11.jpg)
Lymphoma – Staging SystemLymphoma – Staging SystemSubscripts
A Asymptomatic
B Fever > 38o, recurrent
Night sweats drenching, recurrent
Weight loss > 10% body wt in 6 mos
X Bulky disease > 10 cm
or > 1/3 internal transverse diameter @ T5/6 on PA CXR
E Limited extranodal extension from adjacent nodal site
![Page 12: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/12.jpg)
Lymphoma – Essential Staging InvestigationsLymphoma – Essential Staging Investigations
• Biopsy – pathology review• History – B symptoms, PS
• Physical Exam – nodes, liver, spleen, oropharynx
• CBC
• creatinine, liver function tests, LDH, calcium
• Bone marrow aspiration & biopsy
• CT neck, thorax, abdomen, pelvis
![Page 13: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/13.jpg)
Additional Staging InvestigationsAdditional Staging Investigations
• PET or 67Ga scan• CT / MRI of head & neck• Cytology of effusions, ascites• Endoscopy• Endoscopic U/S• MRI - CNS, bone, head & neck presentation
• HIV• CSF cytology - testis, paranasal sinus, peri-orbital,
paravertebral, CNS, epidural, stage IV with bone marrow involvement
for gastric lymphoma
![Page 14: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/14.jpg)
International Prognostic Index for NHLInternational Prognostic Index for NHL
Age > 60
Stage 3, 4
PS ECOG > 2
LDH > normal
Extranodal > 1 site
Number of Risk Factors 5 yr OS**
Low Risk 0-1 75%
Low-Intermediate 2 51%
High-Intermediate 3 43%
High Risk 4-5 26%
**Diffuse large cell lymphoma
![Page 15: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/15.jpg)
Indolent Lymphomae.g. Follicular Gd 1/2, small lymphocytic, marginal zone
Limited Disease ( Stage 1A, 2A if 3 or less adjacent node regions)
• IFRT** 30-35 Gy
• Expect ~ 40% long term FFR
• Alternate:
• CMT
• Observation. Treat when symptomatic.
** Involved Field Radiotherapy. Use 35 Gy for follicular. 30 Gy for SLL, marginal
![Page 16: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/16.jpg)
Indolent Lymphomae.g. Follicular Gd 1/2, small lymphocytic, marginal zone
Advanced Stage( some Stage 2, Stage 3, 4 )
• Palliative RT* for localized symptomatic disease
• Palliative chemotherapy** for disseminated symptomatic disease
• Observation only if low bulk, asymptomatic– Treat when symptomatic
* IFRT 15 – 20 Gy / 5
** CVP, chlorambucil
![Page 17: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/17.jpg)
Aggressive LymphomaAggressive Lymphoma (e.g. Diffuse large B cell)
Stage I, some Stage II
• CHOP** x 3 + IFRT (35-45 Gy)**
Expect ~ 75% long term FFR
Stage III, IV, B symptoms, or bulky disease
CHOP** x 6-8
IFRT (35-45 Gy) to - sites of initial bulk
- residual disease (i.e. PR)
**or CHOP-R (see next slide)
** higher radiation dose if residual disease
![Page 18: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/18.jpg)
Aggressive LymphomaAggressive Lymphoma (e.g. Diffuse large B cell)
CHOP q 21 days• Cyclophosphamide• doxorubicin (formerly Hydroxydaunorubicin)
• vincristine (“Oncovin”)
• Prednisone (p.o. x 5 days)
CHOP-R x 8 ~40 % 3 yr EFS, OS (vs. CHOP x 8)
![Page 19: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/19.jpg)
Rituximab
• Chimeric anti-CD20 mAb– Mouse variable region
– Human constant region (IgG1)
• Direct antitumor effects– Complement-mediated cytotoxicity– Antibody dependent cellular cytotoxicity
• Synergistic activity with chemotherapy
B cellCD20
![Page 20: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/20.jpg)
Chemotherapy – Rituximab Combinations
CHOP – R
• CHOP + rituximab (on day 1)
• GELA study: elderly aggressive NHL . Improved EFS, OS at 3yrs with CHOP-R x 8 vs CHOP x 8.
• MInT study: Interim results suggest superiority of CHOP-R over CHOP in younger (<60) patients.
• CVP – R
• Prolonged TTR in Indolent lymphoma. Probably not covered by most provincial plans
![Page 21: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/21.jpg)
Extranodal LymphomaExtranodal Lymphoma
• Same treatment as nodal lymphoma
Notable Exceptions:• Gastric MALT• Testis• CNS• Skin
![Page 22: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/22.jpg)
MALT Lymphoma Marginal zone B-cell lymphoma of extranodal (MALT) type
• Stomach. assoc. with Helicobacter pylori infection*
• Salivary Gland. assoc with Sjogren’s syndrome*
• Thyroid. assoc with Hashimoto’s thyroiditis*
• Orbital (lacrimal, conjunctiva)
• Other: Waldeyer’s ring, breast, bladder, lung, skin
* chronic antigen stimulation
MALT = “mucosa associated lymphoid tissue”
![Page 23: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/23.jpg)
Gastric MALT LymphomaGastric MALT Lymphoma
• Stage IIEE , H. pylori + PPI, 2 antibiotics (e.g. clarithromycin, amoxicillin)
F/U gastroscopy + Bx q6mo for 2 yrs, then q1yr
• Stage IE, H. pylori - or antibiotic failure IFRT 30 Gy (95% local control)
• Stage 2 or higher Treat as indolent lymphoma + H. pylori eradication
![Page 24: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/24.jpg)
Testis LymphomaTestis Lymphoma
• usually aggressive histology• elderly patients, less tolerant of chemo• high risk relapse need aggressive Tx
High risk of:• extranodal relapse• contralateral testis relapse > 40% by 15yrs
• CNS relapse > 30% 10yr actuarial risk
![Page 25: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/25.jpg)
Testis Lymphoma - TreatmentTestis Lymphoma - Treatment
All pts
Stage 2
3,4
• Orchidectomy (diagnostic & therapeutic)
• CHOP-R x 6• Scrotal radiation 30 Gy / 15
- reduces risk testis recurrence to < 10%
• involved field nodal RT
• CNS chemoprophylaxis– intrathecal MTX
![Page 26: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/26.jpg)
Cutaneous LymphomaCutaneous Lymphoma
• Primary Diffuse Large B-cell
• Primary Cutaneous Anaplastic Large Cell
• Mycosis Fungoides*
Local RT effective for local control
*Mycosis Fungoides usually treated initially with topical Rx
![Page 27: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/27.jpg)
Lymphoma Follow-up
• Hx, Px q3mo for 2 yrs, then q6mo to 5 yrs and then annually.
• CBC, LDH
• CT chest, abdo, pelvis q6mo to 5 yrs
• TSH at least annually after neck irradiation
• Breast cancer screening for women treated with chest radiation 10 yrs post RT
![Page 28: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/28.jpg)
Radiation Planning Principles
1. Best available imaging to accurately localize disease
2. CT based planning to ensure adequate coverage of PTV, and minimize dose to normal tissues
(conventional simulation OK for some sites and palliative treatments)
![Page 29: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/29.jpg)
Involved Field Radiotherapy
1. No rigorous definition of IFRT
2. Most would treat a lymph node region (vs. an individual enlarged node)
3. Typically: 5 – 10 cm margin beyond known disease along axis of nodal group and 2 cm laterally unless constrained by radiosensitive normal tissue
4. Consider treating contiguous nodes if this will not add significant treatment morbidity
5. CT planning of thorax or abdomen
![Page 30: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/30.jpg)
Involved Field Radiotherapy
5. Should we treat the pre-chemotherapy volume or the post-chemotherapy residual disease? … ?
• Information regarding both should be available at time of planning
• Treat entire pre-chemotherapy volume if this will not significantly increase morbidity
• Treat post-chemotherapy transverse diameter of mediastinal or para-aortic nodes
![Page 31: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/31.jpg)
Hodgkin at ease
![Page 32: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/32.jpg)
WHO Classification of Lymphoid Neoplasms
1. Nodular lymphocyte-predominant HL**
2. Classical HL
• Nodular sclerosis HL
• Lymphocyte-rich classical HL**
• Mixed cellularity HL
• Lymphocyte depletion HL
** formerly, both of these were classified as lymphocyte predominance Hodgkin’s Disease
Hodgkin’s Lymphoma ( Hodgkin’s disease)
![Page 33: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/33.jpg)
Hodgkin’s Disease - Staging Investigations
• Biopsy – pathology review• History – B symptoms, pruritis, alcohol pain, PS
• Physical Exam – nodes, liver, spleen, oropharynx
• CBC, ESR• creatinine, liver function tests, LDH,
calcium, albumin• Bone marrow aspiration & biopsy
– if abnormal CBC, Stage 2B or higher
• CT thorax, abdomen, pelvis
![Page 34: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/34.jpg)
Hodgkin’s Disease - Other Investigations
• PET scan• 67Ga scan• Lymphangiogram – if expertise available, no PET
• Pregnancy test• oophoropexy / semen cryopreservation
– if chemotherapy or pelvic RT
• Dental assessment – if oropharyngeal RT
![Page 35: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/35.jpg)
Hodgkin’s Lymphoma
AdvancedIII, IV
Bulky DiseaseB Symptoms
Early Stage
1A, 2A
![Page 36: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/36.jpg)
Hodgkin’s Lymphoma
AdvancedIII, IV
Bulky Disease B Symptoms
Early Stage1A, 2A
FAVOURABLE*
• 1-3 sites
• Age 40
•ESR < 50
• NS, LRCHL
UNFAVOURABLE*
• > 3 sites
• Age > 40
• ESR > 50
• Mixed cellularity
*NCIC HD6 Study Criteria reflecting prognosis when treated with radiation only
![Page 37: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/37.jpg)
Early Stage Hodgkin’s Lymphoma
Favourable Prognosis
• ABVD X 3 - 4
• IFRT 30 Gy / 20
• Fewer cycles ABVD may be adequate. GHSG HD10 study, in progress, compares ABVD x 2 vs. ABVD x 4
• Lower radiation dose may be adequate. GHSG HD10 study and EORTC H9 study, in progress, compare IFRT 20 Gy with 30 Gy (HD10) and 36 Gy (H9)
• Caution: late toxicity data awaited
![Page 38: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/38.jpg)
Favourable Prognosis – Early Stage Hodgkin’s Lymphoma
Some Other Treatment Options
• STNI
• ABVD x 2 + IFRT
• ABVD x 6
• historical gold standard• survival CMT• use if CTx containdicated• but: high risk late toxicity
• as per BCCA guidelines• awaiting clinical trial
results (GHSG HD10)
• awaiting NCIC HD.6 results
Mantle + Para-aortic nodes,spleen 35 Gy/20
![Page 39: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/39.jpg)
Early Stage Hodgkin’s Lymphoma
Unfavourable Prognosis
• ABVD X 4 - 6
• IFRT 30 Gy / 20
• NB: Overlap with favourable prognosis ESHL
![Page 40: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/40.jpg)
Advanced Stage Hodgkin’s Lymphoma
Stage 3, 4, B symptoms, bulky disease
• ABVD X 6 – 8*
• IFRT – sites of bulky disease– sites of residual disease (35 Gy / 20)
* ABVD until 2 cycles past maximum response
![Page 41: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/41.jpg)
ABVD
• doxorubicin (Adriamycin)• Bleomycin• Vinblastine• Dacarbazine
IV Days 1, 15
![Page 42: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/42.jpg)
Very Favourable Prognosis Hodgkin’s Lymphoma
• Stage 1A NLPHL*
• Stage 1A high neck NS, LRCHL
IFRT 35 Gy / 20
*Nodular Lymphocyte Predominant HL–usually localized, peripheral nodal sites–good prognosis, but some late relapses (>10yr)
![Page 43: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/43.jpg)
Hodgkin’s Lymphoma Rough Approximation of Prognosis
FFS OS
Early 80 – 90% 85 – 95%
Advanced 40 – 80%*
* Depending on Hasenclever Prognostic Index: based on Age>45, male, Stage 4, albumin < 4, Hb < 10.5, WBC<600 or >15000
If RT only (STNI): Deaths from 2nd malignancy > deaths from Hodgkin’s disease by 15 – 20 yrs
![Page 44: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/44.jpg)
Combined RT + Chemotherapy (CMT)Unresolved Issues
1. Optimal chemotherapy regimen?
2. Optimal number of chemotherapy cycles?
3. When is radiotherapy required?
4. Radiotherapy CTV?
a) Definition of “involved field”?
5. Radiotherapy dose?
6. Late toxicity compared to STNI
![Page 45: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/45.jpg)
Of Historical Interest: STNI (Subtotal Nodal Irradiation)
• Mantle– cervical, supraclavicular, infraclavicular, mediastinal, hilar
nodes
• Para-aortic nodes, Spleen
• Effective treatment for good prognosis Stage 1, 2A but largely abandoned due high risk late toxicity
• If pressed on exam: “…I don’t believe we’ve treated anyone with mantle RT in my department in the last 5 years. I would have to seek the advice of some of my experienced colleagues regarding this, however from my reading…”
![Page 46: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/46.jpg)
![Page 47: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/47.jpg)
Side Effects of Radiotherapy for Hodgkin’s Lymphoma
1. Depend on Dose/fractionation Site Irradiated volume Chemotherapy
2. - Acute- Subacute- Late
![Page 48: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/48.jpg)
Toxicity of STNI for Hodgkin’s Lymphoma
ACUTE
• Skin erythema• Local alopecia• Xerostomia• Dysphagia• Fatigue WBC, platelets• Para-aortic RT - nausea, vomiting
- diarrhea
![Page 49: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/49.jpg)
SUBACUTE
• Fatigue• Xerostomia• Pneumonitis < 5%, dependent on lung
volume treated• Herpes Zoster• Lhermitte’s Syndrome
Toxicity of EFRT for Hodgkin’s Lymphoma
![Page 50: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/50.jpg)
LATE
• Hypothyroidism• Cardiac
- (CAD, valvular disease, pericarditis)- 5% risk cardiac death in 20 yrs (2-3 x expected)
• 2nd malignancy ( risk of most solid tumors)- esp. breast ca if < 25 yrs at time of RT- Lung ca in smokers- Solid tumour risk rises after 10 years from RT- Absolute Excess Risk ~1% per year
Toxicity of STNI for Hodgkin’s Lymphoma
![Page 51: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/51.jpg)
52 y.o. male with dysphagia
Exam: posterior oropharyngeal mass involving L tonsil, L base of tongue, crossing over midline to involve R base of tongue.
Biopsy: “large cell lymphoma of T-cell derivation with differential diagnosis between nasal type extranodal T-cell lymphoma, and peripheral T-cell lymphoma of unspecified type.”
![Page 52: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/52.jpg)
PANIC
![Page 53: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/53.jpg)
General Principles of Answering Lymphoma Questions - 2
• “First of all, I would take a complete history and perform a full physical examination…”
• “The pathology should be reviewed by an experienced lymphoma pathologist…”
• “This patient’s management should be discussed in a multidisciplinary setting*…”
*At least by haematologist / medical oncologist and radiation oncologist
![Page 54: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/54.jpg)
Clinical Grouping of LymphomasClinical Grouping of Lymphomas
2. Aggressive ( “intermediate grade”)
– Diffuse large B-cell lymphoma 21%
– Primary mediastinal large B cell lymphoma 2%– Anaplastic large T / null cell lymphoma 2%– Peripheral T cell lymphoma 6%– Extranodal NK / T cell lymphoma, nasal type
– Follicular lymphoma Gd 3– Mantle cell lymphoma 6%
Approximate International Incidence
![Page 55: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/55.jpg)
“Aggressive” lymphoma
• CT head, neck, thorax, abdo, pelvis
• MRI head & neck
• CBC, creatinine, LDH, liver enzymes
• Bone marrow aspiration & biopsy
• HIV testing
• Dental consult
![Page 56: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/56.jpg)
DM 005676
CT: “nodular defect arising from posterior aspect of pharynx extending into tonsillar region…3.5 x 1.5 cm…also a prominent nodular structure extending through base of tongue 3.5 x 2.5 cm…. Non-specific cervical lymph nodes, the largest 11 mm…”
No evidence of disease at other sites, normal lab work.
![Page 57: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/57.jpg)
DM 005676
![Page 58: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/58.jpg)
DM 005676
CHOP x 3
Why not CHOP-R?
Planning CT
Supine, in immobilization shell
GTV contoured
![Page 59: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/59.jpg)
DM 005676
PTV: Waldeyer’s Ring. Lateral POP, 6 MV photons, compensators for dose homogeneity, 40 Gy / 20 / 4 wks
![Page 60: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/60.jpg)
31 y.o. female with recent onset fatigue, night sweats, and mass in right neck
Seen in ER: R supraclavicular node ~2 cm
CXR: Huge ant mediastinal mass
Biopsy: Nodular sclerosis type Hodgkin’s disease
CT Chest: “Large, lobulated mass in anterior mediastinum extending from suprasternal notch to cardiophrenic angle…also an enlarged subcarinal node…”
![Page 61: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/61.jpg)
Referral to Radiation Oncology
• History & Physical
• Pathology Review
• Discuss with Haematologist / Medical Oncologist
• CBC, ESR, creatinine, liver enzymes
• CT abdo-pelvis
• 67Ga scan
• Bone marrow aspiration & biopsy
![Page 62: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/62.jpg)
Hodgkin’s Lymphoma, Nodular Sclerosis type
Stage IXB
BW 037843
![Page 63: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/63.jpg)
ABVD x 8 cycles. Residual 4 x 6 cm ant. Mediastinal mass
![Page 64: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/64.jpg)
CT simulation. GTV contoured. CTV = entire mediastinum with 2 cm lateral margin. Move breasts out of field. 6 MV photons. AP POP. 35 Gy / 20 / 4 weeks. Shielding after 25 Gy to protect heart.
![Page 65: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/65.jpg)
AD 036063
26 y.o. female with one year history of intermittent chest pain.
CXR: Anterior mediastinal mass
CT: 6 x 7.5 cm anterior mediastinal mass. No other lymphadenopathy seen.
Biopsy: Non-Hodgkin’s Lymphoma, large cell type. Probably mediastinal sclerosing type.
![Page 66: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/66.jpg)
![Page 67: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/67.jpg)
Referral to Radiation Oncology
• History & Physical
• Pathology Review
• Discuss with Haematologist / Medical Oncologist
• CBC, LDH, creatinine, liver enzymes
• CT abdo-pelvis
• 67Ga scan
• Bone marrow aspiration & biopsy
What Stage is this patient?
![Page 68: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/68.jpg)
![Page 69: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/69.jpg)
Bulky disease on CXR. Stage IXA
![Page 70: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/70.jpg)
![Page 71: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/71.jpg)
CHOP x 6 cycles. 2 x 0.9 cm residual mass
RT to mediastinum: 40 Gy / 20
![Page 72: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/72.jpg)
![Page 73: LYMPHOMA Dr. P. Cross 10 th Annual National Preparatory Course in Clinical and Radiation Oncology](https://reader035.vdocuments.us/reader035/viewer/2022062801/56649e725503460f94b719c8/html5/thumbnails/73.jpg)